CLAIMS

What is claimed is:

1. Use of a HPV vaccine composition in the manufacture of a medicament for treating a patient having cancer, wherein said patient is 27 years of age or older or is previously not immunized with an HPV vaccine, and wherein said HPV vaccine is free of host-cell peptide, polypeptide, or protein or a degradant product thereof wherein said composition is to be administered as a first dose of the HPV vaccine, a second dose of the HPV vaccine about one month to about three months after the first dose; and a third dose of the HPV vaccine about five months to about seven months after the first dose.
2. The use according to claim 1 wherein the second dose of HPV vaccine is to be administered about two months after administering the first dose and the third dose of HPV vaccine is to be administered in six months after administering the first dose.
3. The use according to claim 1 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent (types 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine comprising HPV L1 proteins.
4. The use according to claim 1 wherein the vaccine is substantially free of host-cell early antigen, E6 or E7.
5. The use according to claim 1 and excludes administering an additional or other immunostimulant or adjuvant.
6. The use according to claim 1 wherein the size of the cancer is substantially reduced.
7. The use according to claim 1 wherein the cancer is eliminated.
8. The use according to claim 1 whereby the incidence of recurrence of the cancer is reduced.
9. The use according to claim 1 wherein each dose of HPV vaccine is 0.5 ml.
10. The use according to claim 1 wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and melanoma.

11. The use according to claim 1 wherein a positive diagnosis of cancer, diagnosis of benign tumor, or diagnosis of HPV infection is established in the patient prior to administering the first dose of HPV vaccine.

12. The use according to claim 1, wherein the HPV vaccine is to be administered directly to the cancer or an area immediately surrounding the cancer.

13. The use according to claim 12, wherein the third dose of the HPV vaccine is optional.

14. The use according to claim 1, wherein the vaccine is to be administered by injection.

15. The use according to claim 1, wherein the HPV vaccine is to be administered systemically.

16. The use according to claim 1, wherein the HPV vaccine is to be systemically administered to the patient, and to be administered directly to the cancer or an area immediately surrounding the cancer.

17. The use according to claim 16, said use comprising a second dose of the HPV vaccine to be administered systemically and directly to the cancer or area immediately surrounding the cancer of the patient about one month to about three months after the first administration.

18. The use according to claim 16, said use comprising

a third dose of the HPV vaccine to be administered systemically and directly to the cancer or area immediately surrounding the cancer of the patient about five months to about seven months after the first dose.

19. The use according to claim 17 wherein the second dose of HPV vaccine is to be administered about two months after administering the first dose.

20. The use according to claim 18 wherein the third dose of HPV vaccine is to be administered about six months after administering the first dose.